Literature DB >> 19474189

S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy.

Jian-Kang Chen, Jianchun Chen, George Thomas, Sara C Kozma, Raymond C Harris.   

Abstract

Removal of one kidney stimulates synthesis of RNA and protein, with minimal DNA replication, in all nephron segments of the remaining kidney, resulting in cell growth (increase in cell size) with minimal cell proliferation (increase in cell number). In addition to the compensatory renal hypertrophy caused by nephron loss, pathophysiological renal hypertrophy can occur as a consequence of early uncontrolled diabetes. However, the molecular mechanism underlying renal hypertrophy in these conditions remains unclear. In the present study, we report that deletion of S6 kinase 1 (S6K1) inhibited renal hypertrophy seen following either contralateral nephrectomy or induction of diabetes. In wild-type mice, hypertrophic stimuli increased phosphorylation of 40S ribosomal protein S6 (rpS6), a known target of S6K1. Immunoblotting analysis revealed that S6K1(-/-) mice exhibited moderately elevated basal levels of rpS6, which did not increase further in response to the hypertrophic stimuli. Northern blotting indicated a moderate upregulation of S6K2 expression in the kidneys of S6K1(-/-) mice. Phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1, another downstream target of the mammalian target of rapamycin (mTOR), was stimulated to equivalent levels in S6K1(-/-) and S6K1(+/+) littermates during renal hypertrophy, indicating that mTOR was still activated in the S6K1(-/-) mice. The highly selective mTOR inhibitor, rapamycin, inhibited increased phosphorylation of rpS6 and blocked 60-70% of the hypertrophy seen in wild-type mice but failed to prevent the approximately 10% hypertrophy seen in S6K1(-/-) mice in response to uninephrectomy (UNX) although it did inhibit the basal rpS6 phosphorylation. Thus the present study provides the first genetic evidence that S6K1 plays a major role in the development of compensatory renal hypertrophy as well as diabetic renal hypertrophy and indicates that UNX- and diabetes-mediated mTOR activation can selectively activate S6K1 without activating S6K2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474189      PMCID: PMC2739710          DOI: 10.1152/ajprenal.00186.2009

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  56 in total

Review 1.  TOR, a central controller of cell growth.

Authors:  T Schmelzle; M N Hall
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway.

Authors:  K A Martin; S S Schalm; C Richardson; A Romanelli; K L Keon; J Blenis
Journal:  J Biol Chem       Date:  2000-12-06       Impact factor: 5.157

Review 3.  TOR signaling in growth and metabolism.

Authors:  Stephan Wullschleger; Robbie Loewith; Michael N Hall
Journal:  Cell       Date:  2006-02-10       Impact factor: 41.582

4.  A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy.

Authors:  Myung-Ja Lee; Denis Feliers; Meenalakshmi M Mariappan; Kavithalakshmi Sataranatarajan; Lenin Mahimainathan; Nicolas Musi; Marc Foretz; Benoit Viollet; Joel M Weinberg; Goutam Ghosh Choudhury; Balakuntalam S Kasinath
Journal:  Am J Physiol Renal Physiol       Date:  2006-10-03

Review 5.  Ribosomal S6 kinase signaling and the control of translation.

Authors:  A Dufner; G Thomas
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

6.  G1 kinases and transforming growth factor-beta signaling are associated with a growth pattern switch in diabetes-induced renal growth.

Authors:  H C Huang; P A Preisig
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

7.  Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease.

Authors:  Kathryn Elizabeth White; Rudolf William Bilous
Journal:  J Am Soc Nephrol       Date:  2000-09       Impact factor: 10.121

Review 8.  Physiological myocardial hypertrophy: how and why?

Authors:  Daniele Catalucci; Michael V G Latronico; Oyvind Ellingsen; Gianluigi Condorelli
Journal:  Front Biosci       Date:  2008-01-01

Review 9.  Mammalian target of rapamycin as a therapeutic target in oncology.

Authors:  Robert T Abraham; Christina H Eng
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

10.  SKAR is a specific target of S6 kinase 1 in cell growth control.

Authors:  Celeste J Richardson; Mark Bröenstrup; Diane C Fingar; Kristina Jülich; Bryan A Ballif; Steven Gygi; John Blenis
Journal:  Curr Biol       Date:  2004-09-07       Impact factor: 10.834

View more
  34 in total

1.  Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis.

Authors:  P Darwin Bell; Wayne Fitzgibbon; Kelli Sas; Antine E Stenbit; May Amria; Amber Houston; Ryan Reichert; Sandra Gilley; Gene P Siegal; John Bissler; Mehmet Bilgen; Peter Cheng-te Chou; Lisa Guay-Woodford; Brad Yoder; Courtney J Haycraft; Brian Siroky
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

2.  Autophagy Portends the Level of Cardiac Hypertrophy in Experimental Hypertensive Swine Model.

Authors:  Xin Zhang; Matthew E Gibson; Zi-Lun Li; Xiang-Yang Zhu; Kyra L Jordan; Amir Lerman; Lilach O Lerman
Journal:  Am J Hypertens       Date:  2015-04-22       Impact factor: 2.689

3.  Cre/loxP approach-mediated downregulation of Pik3c3 inhibits the hypertrophic growth of renal proximal tubule cells.

Authors:  Ting Liu; Jialing Yuan; Caihong Dai; Jinxian Xu; Shude Li; Benjamin D Humphreys; Daniel T Kleven; Jian-Kang Chen
Journal:  J Cell Physiol       Date:  2020-05-31       Impact factor: 6.384

4.  mVps34 deletion in podocytes causes glomerulosclerosis by disrupting intracellular vesicle trafficking.

Authors:  Jianchun Chen; Mystie X Chen; Agnes B Fogo; Raymond C Harris; Jian-Kang Chen
Journal:  J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 10.121

Review 5.  Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II.

Authors:  Ravi Nistala; Adam Whaley-Connell
Journal:  Mol Cell Endocrinol       Date:  2013-02-15       Impact factor: 4.102

6.  Blocking rpS6 Phosphorylation Exacerbates Tsc1 Deletion-Induced Kidney Growth.

Authors:  Huijuan Wu; Jianchun Chen; Jinxian Xu; Zheng Dong; Oded Meyuhas; Jian-Kang Chen
Journal:  J Am Soc Nephrol       Date:  2015-08-21       Impact factor: 10.121

Review 7.  Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.

Authors:  Daniel Fantus; Natasha M Rogers; Florian Grahammer; Tobias B Huber; Angus W Thomson
Journal:  Nat Rev Nephrol       Date:  2016-08-01       Impact factor: 28.314

8.  Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway.

Authors:  Adam T Whaley-Connell; Javad Habibi; Ravi Nistala; Vincent G DeMarco; Lakshmi Pulakat; Melvin R Hayden; Tejaswini Joginpally; Carlos M Ferrario; Alan R Parrish; James R Sowers
Journal:  Am J Nephrol       Date:  2011-12-24       Impact factor: 3.754

9.  EGF Receptor-Dependent YAP Activation Is Important for Renal Recovery from AKI.

Authors:  Jianchun Chen; Huaizhou You; Yan Li; You Xu; Qian He; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2018-08-02       Impact factor: 10.121

10.  Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats.

Authors:  Kumiko Nishihara; Satohiro Masuda; Shunsaku Nakagawa; Atsushi Yonezawa; Takaharu Ichimura; Joseph V Bonventre; Ken-ichi Inui
Journal:  Am J Physiol Renal Physiol       Date:  2010-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.